WASHINGTON, Dec. 23 -- National Institutes of Health has issued a notice called: Prospective Grant of an Exclusive Patent License: Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1, or TRAT1.
The notice was published in the Federal Register on Dec. 23 by Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute.
Summary: The Eunice Kennedy ShriverNational Institute of Child Health and Human Development, an institute of the National Institutes of Health, United States Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patent applications listed in the Supplementary Informationsection of this notice to EnZet...